AKBA – Akebia Therapeutics Inc.
Akebia Therapeutics, Inc.AKBA
$1.80Name : Akebia Therapeutics, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $392,725,760.00
EPSttm : -0.22
Akebia Therapeutics, Inc.
$1.80
5.76%$0.11Float Short %
6.9
Margin Of Safety %
Put/Call OI Ratio
0.23
EPS Next Q Diff
0.05
EPS Last/This Y
EPS This/Next Y
0.12
Price
1.79
Target Price
7.17
Analyst Recom
1
Performance Q
Relative Volume
1.84
Beta
0.91
Ticker: AKBA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | AKBA | 2.39 | 0.22 | 0.08 | 24857 |
| 2025-01-24 | AKBA | 2.38 | 0.22 | 0.13 | 25888 |
| 2025-01-27 | AKBA | 2.3 | 0.23 | 0.14 | 26033 |
| 2025-01-28 | AKBA | 2.28 | 0.23 | 0.07 | 25999 |
| 2025-01-29 | AKBA | 2.3 | 0.23 | 0.04 | 26022 |
| 2025-01-30 | AKBA | 2.3 | 0.23 | 0.02 | 26171 |
| 2025-01-31 | AKBA | 2.23 | 0.23 | 0.34 | 26160 |
| 2025-02-03 | AKBA | 2.12 | 0.25 | 0.12 | 26355 |
| 2025-02-04 | AKBA | 2.13 | 0.25 | 0.10 | 26634 |
| 2025-02-05 | AKBA | 2.17 | 0.25 | 1.67 | 26566 |
| 2025-02-06 | AKBA | 2.16 | 0.26 | 0.13 | 26666 |
| 2025-02-07 | AKBA | 2.14 | 0.26 | 0.12 | 26681 |
| 2025-02-10 | AKBA | 2.11 | 0.25 | 0.15 | 27256 |
| 2025-02-11 | AKBA | 2.1 | 0.25 | 0.01 | 27321 |
| 2025-02-12 | AKBA | 2.12 | 0.25 | 0.00 | 27402 |
| 2025-02-13 | AKBA | 2.14 | 0.25 | 0.00 | 27479 |
| 2025-02-14 | AKBA | 2.12 | 0.24 | 0.00 | 28753 |
| 2025-02-18 | AKBA | 2.08 | 0.24 | 0.02 | 28766 |
| 2025-02-19 | AKBA | 1.97 | 0.24 | 0.01 | 28732 |
| 2025-02-20 | AKBA | 1.9 | 0.22 | 0.21 | 30222 |
| 2025-02-21 | AKBA | 1.795 | 0.23 | 0.26 | 31143 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | AKBA | 2.39 | 0.0 | - | -0.26 |
| 2025-01-24 | AKBA | 2.38 | 0.0 | - | -0.26 |
| 2025-01-27 | AKBA | 2.30 | 0.0 | - | -0.26 |
| 2025-01-28 | AKBA | 2.29 | 0.0 | - | -0.26 |
| 2025-01-29 | AKBA | 2.30 | 0.0 | - | -0.26 |
| 2025-01-30 | AKBA | 2.30 | 0.0 | - | -0.26 |
| 2025-01-31 | AKBA | 2.23 | 0.0 | - | -0.26 |
| 2025-02-03 | AKBA | 2.12 | 0.0 | - | -0.26 |
| 2025-02-04 | AKBA | 2.14 | 0.0 | - | -0.26 |
| 2025-02-05 | AKBA | 2.16 | 0.0 | - | -0.26 |
| 2025-02-06 | AKBA | 2.16 | 0.0 | - | -0.26 |
| 2025-02-07 | AKBA | 2.14 | 0.0 | - | -0.26 |
| 2025-02-10 | AKBA | 2.10 | 0.0 | - | -0.26 |
| 2025-02-11 | AKBA | 2.10 | 0.0 | - | -0.26 |
| 2025-02-12 | AKBA | 2.12 | 0.0 | - | -0.26 |
| 2025-02-13 | AKBA | 2.14 | 0.0 | - | -0.26 |
| 2025-02-14 | AKBA | 2.13 | 0.0 | - | -0.26 |
| 2025-02-18 | AKBA | 2.07 | 0.0 | - | -0.26 |
| 2025-02-19 | AKBA | 1.98 | 0.0 | - | -0.26 |
| 2025-02-20 | AKBA | 1.90 | 0.0 | - | -0.26 |
| 2025-02-21 | AKBA | 1.79 | 0.0 | - | -0.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | AKBA | 0.00 | 6.46 | 8.03 |
| 2025-01-24 | AKBA | 0.00 | 6.46 | 8.03 |
| 2025-01-27 | AKBA | 0.00 | 6.57 | 8.03 |
| 2025-01-28 | AKBA | 0.00 | 6.57 | 8.67 |
| 2025-01-29 | AKBA | 0.00 | 6.57 | 8.67 |
| 2025-01-30 | AKBA | 0.00 | 6.57 | 8.67 |
| 2025-01-31 | AKBA | 0.00 | 6.57 | 8.67 |
| 2025-02-03 | AKBA | 0.00 | 6.34 | 8.67 |
| 2025-02-04 | AKBA | 0.00 | 6.34 | 8.67 |
| 2025-02-05 | AKBA | -2.58 | 6.34 | 8.67 |
| 2025-02-06 | AKBA | -2.58 | 6.34 | 8.67 |
| 2025-02-07 | AKBA | -2.58 | 6.34 | 8.67 |
| 2025-02-10 | AKBA | -2.58 | 6.83 | 8.72 |
| 2025-02-11 | AKBA | -2.34 | 6.83 | 8.72 |
| 2025-02-12 | AKBA | -2.34 | 6.83 | 7.00 |
| 2025-02-13 | AKBA | -2.34 | 6.83 | 7.00 |
| 2025-02-14 | AKBA | -2.34 | 6.83 | 7.00 |
| 2025-02-18 | AKBA | -2.34 | -0.32 | 7.00 |
| 2025-02-19 | AKBA | -2.34 | -0.32 | 7.00 |
| 2025-02-20 | AKBA | -2.34 | -0.32 | 7.00 |
| 2025-02-21 | AKBA | -3.11 | -0.32 | 6.90 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.1
Avg. EPS Est. Current Quarter
-0.04
Avg. EPS Est. Next Quarter
-0.06
Insider Transactions
-3.11
Institutional Transactions
-0.32
Beta
0.91
Average Sales Estimate Current Quarter
40
Average Sales Estimate Next Quarter
37
Fair Value
Quality Score
22
Growth Score
35
Sentiment Score
41
Actual DrawDown %
86.9
Max Drawdown 5-Year %
-98.2
Target Price
7.17
P/E
Forward P/E
PEG
P/S
2.31
P/B
P/Free Cash Flow
EPS
-0.22
Average EPS Est. Cur. Y
-0.26
EPS Next Y. (Est.)
-0.14
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-27.07
Relative Volume
1.84
Return on Equity vs Sector %
72
Return on Equity vs Industry %
83.4
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.06
EBIT Estimation
Akebia Therapeutics, Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 167
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today
news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance
stock history AKBA – Akebia Therapeutics Inc. invest stock market
stock prices AKBA premarket after hours
ticker AKBA fair value insiders trading